J&J Locks Theravance’s Phase I Inflammatory Bowel Disease Asset for US$1 B
By Natasha Berry
Pharma Deals Review: Vol 2018 Issue 2 (Table of Contents)
Published: 16 Feb-2018
DOI: 10.3833/pdr.v2018.i2.2304 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Janssen Biotech (division of Johnson & Johnson (J&J)) has announced a collaboration with a subsidiary of Theravance Biopharma for the co-development and commercialization of TD-1473, an asset being pursued for inflammatory bowel disease (IBD)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS